FCGR3A and cancer: It will be important to determine in future studies whether the engineering of NK92 cells or primary NK cells derived from pluripotent stem cells to express CD16a/S197P will prevent the down-regulation of this key FcγR upon cell activation in the tumor environment and enhance their ADCC potency and cancer cell killing.